PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY), a global leader in oncology drug development, today announced that more than 95 scientific abstracts on 13 of its oncology compounds will be featured at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 4-8.
New data on the novel immuno-oncology agent ipilimumab will be presented. Ipilimumab is a T-cell potentiator that specifically blocks the inhibitory signal of CTLA-4 (cytotoxic T lymphocyte-associated antigen 4). Results from a Phase 3 study of ipilimumab in patients with previously-treated advanced melanoma have been selected for presentation in a plenary session on Sunday, June 6. The company is also investigating the potential of ipilimumab in other solid tumors and data from a randomized Phase 2 study in non-small cell lung cancer will be presented for the first time at ASCO.
“We are excited by the potential of immuno-oncology, an entirely new paradigm in the treatment of multiple types of cancer in which a patient’s own immune system is activated to fight cancer cells,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. “We are leading the way with ipilimumab, the most advanced investigational compound in our immuno-oncology portfolio, in testing this new paradigm and we look forward to presenting results from the ipilimumab clinical development program at this year’s American Society of Clinical Oncology Annual Meeting.”
Bristol-Myers Squibb will also present results on another immuno-oncology compound in the company’s portfolio known as MDX-1106, which targets PD-1 or programmed death-1. PD-1 is an inhibitory receptor expressed on activated T-cells whose signaling may be used by tumor cells to suppress antitumor immunity. Bristol-Myers Squibb is developing MDX-1106 in partnership with Ono Pharmaceutical.
“Bristol-Myers Squibb has been committed to shaping and advancing cancer care for more than 40 years. As a leading BioPharma company, we are dedicated to discovering and developing innovative medicines for cancer patients. Data being presented at this year’s annual meeting reflect the breadth and depth of our oncology portfolio and highlight the diverse approach we take to investigating new treatments for cancer,” added Sigal.
Bristol-Myers Squibb and its partner, Otsuka, will present data from the Phase 3 head-to-head trial evaluating SPRYCEL® (dasatinib) vs. Gleevec®* (imatinib mesylate) in the first-line treatment of chronic-phase CML (known as DASISION). These results will be presented as a late-breaking abstract on Monday, June 7. Long-term data from a Phase 3 study that evaluated the safety and efficacy of SPRYCEL over four years in the treatment of CML patients with resistance or intolerance to Gleevec will also be presented. Additional data will be presented on the investigational use of SPRYCEL in multiple non-hematologic cancers, including prostate and breast cancer.
ERBITUX ® (cetuximab) will be highlighted in abstracts that span a wide range of investigational uses in solid tumors such as colorectal, lung, pancreatic and breast. On Sunday, June 6, data from a pooled analysis of two studies evaluating ERBITUX in the first-line treatment of colorectal cancer according to KRAS/BRAF status will be featured in an oral presentation. IXEMPRA® (ixabepilone) will be featured in abstracts reporting results in combination regimens with other chemotherapies or targeted agents in breast cancer and other tumor types.
Elotuzumab, which Bristol-Myers Squibb is co-developing with Abbott, is currently in Phase 2 development and will be featured in abstracts reporting on its potential in multiple myeloma. Elotuzumab is an antibody specifically designed to bind to the CS1 glycoprotein, a highly expressed cell surface protein in multiple myeloma.
Other investigational compounds from the Bristol-Myers Squibb oncology portfolio including brivanib, CT-322, BMS 753493 (an epothilone folate), BMS 690514 (EVRI) and BMS 754807 (an IGF-IR), will also be featured at ASCO.
About Bristol-Myers Squibb
Full prescribing information for ERBITUX, SPRYCEL and IXEMPRA is available at http://www.bms.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the compounds described in this release will receive regulatory approvals or, if approved, that they will become commercially successful. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2009, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
* Gleevec® is a registered trademark of Novartis AG
KEYWORDS: United States North America Illinois New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical